首页 >
法规速递
-
Document: Aprepitant, hard capsules, 80mg, 125mg, 80+125mg and powder for oral suspension 125mg product-specific bioequivalence guidance-2025/1/31
2025-02-05查看详情 > -
Page: Procurement-2025/1/30
2025-02-05查看详情 > -
Page: Union Product Database: release notes-2025/1/30
2025-02-05查看详情 > -
Document: COMP work plan 2025-2025/1/30
2025-02-05查看详情 > -
Page: One Health approach-2025/1/30
2025-02-05查看详情 > -
Page: History of EMA-2025/1/30
2025-02-05查看详情 > -
Document: Draft reflection paper on the qualification of non-mutagenic impurities-2025/1/30
2025-02-05查看详情 > -
Document: Procedural advice for post-orphan medicinal product designation activities: Guidance for sponsors-2025/1/30
2025-02-05查看详情 > -
Page: Falsified medicines: overview-2025/1/30
2025-02-05查看详情 > -
Document: Committee on Herbal Medicinal Products (HMPC): Work Plan 2025-2025/1/30
2025-02-05查看详情 >
